Kura Oncology announces availability of press release on darlifarnib-cabozantinib RCC data update

Kura Oncology, Inc.

Kura Oncology, Inc.

KURA

0.00
  • Kura Oncology released an announcement on updated long-term Phase 1a FIT-001 data for darlifarnib with cabozantinib in advanced clear cell renal cell carcinoma.
  • Data will be presented in an oral session at the Kidney Cancer Research Summit on July 24, 2026.
  • A randomized Phase 1b study comparing the combination with cabozantinib alone remains ongoing to support Phase 3 dose selection.
  • Kura scheduled a virtual investor call for July 27, 2026, with webcast details at www.kuraoncology.com.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief on July 14, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.